Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 12/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679051 | 0.86 | SMN1; SMN2 (0.37) | GPR84DAOPKMCYP1A2CYP2C19 | |
| SCHEMBL7681735 | 0.80 | KMT2A (0.48) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7675267 | 0.80 | CYP1A2 (0.44) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7686410 | 0.79 | CYP1A2 (0.54) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7681871 | 0.77 | HTT (0.50) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7679436 | 0.76 | DAO (0.37) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7679685 | 0.76 | KMT2A (0.50) | GPR84CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL14765232 | 0.76 | CYP1A2 (0.54) | GPR84CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL7681977 | 0.74 | CYP1A2 (0.40) | GPR84DAOCYP1A2CYP2C19KMT2A | |
| SCHEMBL7682145 | 0.73 | DAO (0.42) | GPR84DAOCYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5441970-A | Administering angiotensin II antagonists to treat congestive heart failure or hypertension | G. D. SEARLE & CO. (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0579766-A1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |